Company / Cash & Equivalents
Akebia Therapeutics, Inc. Cash & Equivalents History
FY2014-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$184.8M
FY2025
5-year range
$42.9M / $228.7M
FY2021-FY2025
Trend
+256.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents changed +256% YoY in FY2025, a notable deviation from the 9-year average annual change of +249%.
Based on SEC 10-K filings.
$185M in FY2025 with a 10-year CAGR of +24.2%.
Improved from $43M to $185M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +26.9%
- 5-Year CAGR
- +4.6%
- 10-Year CAGR
- +24.2%
Key checks
Key Insights
- 5-year CAGR of +4.6%, indicating consistent growth.
- In FY2025, cash & equivalents increased 256.4% year-over-year.
- Peak cash & equivalents was recorded in FY2021.
- Lowest cash & equivalents in the period was in FY2014.
Company context
Key Data Points
- Altman Z-Score -2.76 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $184.8M | +256.4% |
| FY2024 | $51.9M | +20.8% |
| FY2023 | $42.9M | -52.6% |
| FY2022 | $90.5M | -60.4% |
| FY2021 | $228.7M | +55.1% |
| FY2020 | $147.4M | +110.2% |
| FY2019 | $70.2M | -62.6% |
| FY2018 | $187.3M | +783.0% |
| FY2015 | $21.2M | +1192.8% |
| FY2014 | $1.6M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026